Currently there’s no cure for Huntington's disease, yet, various medications are available to help manage its symptoms. Understanding how these medications work inside the brain can offer a clearer picture of treatment strategies and why certain drugs are chosen.
This article looks at the science behind these treatments, focusing on the medication for Huntington's and how it aims to make a difference.
Quick Brief
Medications for Huntington's disease often work by targeting neurotransmitters, the chemical messengers in the brain, to manage symptoms.
VMAT2 inhibitors, like deutetrabenazine, help control involuntary movements (chorea) by reducing dopamine levels.
Antipsychotic drugs can manage movement issues, irritability, and psychosis by blocking dopamine receptors.
Antidepressants, such as SSRIs and SNRIs, are used to address mood changes like depression and anxiety associated with HD.
Some new treatments are exploring ways to directly target the huntingtin protein or the genetic changes that cause HD.
The goal of many current medications is to improve quality of life by managing specific symptoms.
Research continues to explore new ways to treat HD, aiming for therapies that can slow or stop disease progression.
What Is the Role of Neurotransmitters in Targeting Huntington's Symptoms?
Huntington's disease (HD) is a condition that affects the brain, and at its core, it involves changes in how brain cells communicate. This communication happens through chemical messengers called neurotransmitters.
In HD, the balance of these messengers can get disrupted, leading to many of the symptoms people experience. One key player is dopamine, a neurotransmitter involved in controlling movement.
When dopamine levels are unbalanced, it can contribute to the involuntary movements, or chorea, seen in HD. But it's not just dopamine; other neurotransmitters like serotonin and GABA are also important for mood, behavior, and overall mental well-being, and their levels or activity can be altered in HD.
How Does Modulating Brain Chemistry Provide Symptom Relief?
Since HD involves a complex interplay of neurotransmitter changes, the strategy for managing its symptoms often involves trying to restore a better balance.
Medications don't cure HD, but they can make a significant difference in managing its effects. The goal is to target specific neurotransmitter systems that are contributing to particular symptoms.
For example, if involuntary movements are a major concern, medications might be used to adjust dopamine levels. If mood changes like depression or anxiety are prominent, other medications might focus on systems involving serotonin or norepinephrine.
How Do VMAT2 Inhibitors Specifically Target Huntington's Chorea?
Why Is VMAT2 a Critical Target for Movement Control?
In Huntington's disease, the balance of dopamine can become disrupted, contributing to the involuntary movements, or chorea, that are characteristic of the brain condition. This is where drugs that target the vesicular monoamine transporter 2 (VMAT2) come into play.
VMAT2 is a protein found in nerve cells. Its job is to package neurotransmitters, like dopamine, into vesicles, which are small sacs within the cell. These vesicles then store the neurotransmitters until they are needed for signaling between brain cells.
By influencing how VMAT2 works, we can affect the amount of dopamine available for transmission.
What Is the Biological Mechanism for Reducing Dopamine Transmission?
VMAT2 inhibitors work by blocking the action of this transporter protein. When VMAT2 is inhibited, it can't effectively package dopamine into vesicles.
This leads to less dopamine being stored and, consequently, less dopamine being released into the synapse – the tiny gap between nerve cells where communication occurs. Reducing the amount of dopamine available for transmission can help to lessen the severity of chorea.
Tetrabenazine was one of the first medications approved by the FDA specifically for treating chorea in HD, and it works through this mechanism.
How Does Deutetrabenazine Refine the Pharmacological Approach?
More recently, medications like deutetrabenazine have been developed. Deutetrabenazine is a modified form of tetrabenazine.
The "deuterium-labeled" aspect means that certain hydrogen atoms in the molecule have been replaced with deuterium, a heavier form of hydrogen. This subtle change can affect how the drug is processed by the body.
Specifically, deutetrabenazine is metabolized more slowly than tetrabenazine. This slower breakdown can lead to more stable levels of the drug in the system, potentially allowing for less frequent dosing and a more consistent effect on dopamine levels.
Like its predecessor, deutetrabenazine works by inhibiting VMAT2 to help manage the involuntary movements associated with Huntington's disease.
What Is the Dual Role of Antipsychotics in Managing Huntington's?
How Does Blocking Dopamine Receptors Control Excessive Movement?
Antipsychotic medications, often used for conditions like schizophrenia, can also play a role in managing certain symptoms of Huntington's disease. These drugs primarily work by affecting dopamine, a key neurotransmitter.
In HD, dopamine pathways can become dysregulated, contributing to involuntary movements like chorea. Antipsychotics, particularly older or "typical" ones, often work by blocking dopamine receptors in the brain. This blockade can help reduce the intensity and frequency of these motor symptoms.
By interfering with dopamine's signal, these medications can offer a degree of control over disruptive movements.
In What Ways Do These Drugs Address Irritability and Psychosis?
Beyond their impact on movement, antipsychotics can be quite useful for addressing behavioral and psychological symptoms that sometimes accompany HD. These can include irritability, agitation, and even psychosis, which involves a loss of touch with reality.
The same dopamine-blocking action that helps with chorea can also help to calm an overactive brain state associated with these symptoms. Some antipsychotics also interact with other neurotransmitter systems, like serotonin, which can further contribute to mood stabilization and a reduction in anxiety or aggressive behaviors.
Why Are Atypical Antipsychotics Often Preferred Over Older Agents?
When considering antipsychotics for HD, there's a distinction between "typical" (older) and "atypical" (newer) agents. While typical antipsychotics are effective at blocking dopamine, neuroscience tells us that they often come with a higher risk of movement-related side effects, such as parkinsonism (stiffness, slowness) and tardive dyskinesia (involuntary movements that can be permanent).
Atypical antipsychotics, on the other hand, tend to have a more balanced effect on neurotransmitters, including dopamine and serotonin. This often translates to a better side effect profile, with a lower likelihood of causing or worsening motor symptoms.
They are frequently preferred in HD management because they can target both movement and behavioral symptoms with potentially fewer motor-related drawbacks.
How Are Mood and Behavioral Imbalances Restored via Medication?
How Do SSRIs Alleviate Depression and Anxiety in Patients?
Selective serotonin reuptake inhibitors, commonly known as SSRIs, are a class of medications often used to address depression and anxiety. They work by increasing the availability of serotonin, a neurotransmitter that plays a role in mood regulation.
SSRIs achieve this by blocking the reabsorption (reuptake) of serotonin into neurons, leaving more of it available in the synaptic cleft to transmit signals. This increased serotonin activity can help to lift mood and reduce feelings of anxiety.
What Is the Role of SNRIs and Other Antidepressant Classes?
Beyond SSRIs, other types of antidepressants may also be employed. Serotonin-norepinephrine reuptake inhibitors (SNRIs) work similarly to SSRIs but also affect norepinephrine, another neurotransmitter involved in mood and alertness.
By influencing both serotonin and norepinephrine systems, SNRIs can offer a different approach to managing depressive and anxious symptoms.
In some cases, other classes of antidepressants might be considered based on a person's specific symptom profile and response to treatment.
Why Is Addressing Apathy a More Complex Pharmacological Challenge?
Apathy, characterized by a lack of motivation and interest, is another common behavioral change seen in Huntington's disease. Unlike depression, which is often linked to specific neurotransmitter imbalances that can be targeted by SSRIs or SNRIs, apathy presents a more complex pharmacological challenge.
Currently, there are no specific medications approved to directly treat apathy in HD. Treatment often involves a combination of strategies, including behavioral interventions and sometimes off-label use of medications that might indirectly help, though their effectiveness can vary significantly.
Why Is Understanding Drug Mechanisms Vital for Huntington's Care?
How Does Connecting Side Effects to Drug Actions Benefit Patients?
When a doctor prescribes medication for Huntington's disease, it's not just about treating a symptom. It's about understanding how that medicine interacts with the complex chemistry of the brain.
For instance, medications that affect dopamine levels, like some used for chorea, can sometimes lead to other changes. Knowing that a drug targets dopamine helps explain why someone might experience certain side effects, such as changes in mood or energy levels.
This knowledge helps patients and their doctors have more informed discussions about treatment.
How Does This Knowledge Inform Conversations with Your Neurologist?
Understanding the basic way a medication works can make conversations with your neurologist much more productive. Instead of just saying "this medicine isn't working" or "I'm having this side effect," you can provide more context.
For example, if a medication is designed to reduce dopamine activity, and you're experiencing increased irritability, you can discuss whether this is a known effect of dopamine modulation or something else entirely. This shared understanding allows for more precise adjustments to your treatment plan. It also helps in evaluating new treatments, as understanding the proposed mechanism of action can give insight into its potential benefits and risks.
Here's a simplified look at how some medication types relate to brain chemistry:
Medication Type | Primary Target in HD Symptoms | Potential Brain Chemistry Effect |
|---|---|---|
VMAT2 Inhibitors | Chorea | Reduces the amount of dopamine available for release |
Antipsychotics | Chorea, Irritability, Psychosis | Blocks dopamine receptors |
SSRIs/SNRIs | Depression, Anxiety | Affects serotonin and/or norepinephrine levels |
Emerging research | May help protect nerve cells from stress, potentially impacting disease course |
This kind of information isn't meant to replace medical advice, but it can serve as a foundation for better communication about your care.
What Is the Future Landscape for Huntington's Disease Medication?
The landscape of Huntington's disease treatment is evolving. While current medications primarily manage symptoms like involuntary movements, research is actively exploring new ways to address the disease's root causes.
From therapies aiming to reduce toxic proteins to those supporting brain cell health and function, a variety of approaches are in development. These investigational treatments, including gene therapies, small molecules, and antibody-based strategies, are in different stages of research and clinical trials.
The ongoing scientific effort offers hope for future advancements that could potentially alter the course of Huntington's disease.
References
Cepeda, C., Murphy, K. P., Parent, M., & Levine, M. S. (2014). The role of dopamine in Huntington's disease. Progress in brain research, 211, 235–254. https://doi.org/10.1016/B978-0-444-63425-2.00010-6
Frank S. (2010). Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease. Neuropsychiatric disease and treatment, 6, 657–665. https://doi.org/10.2147/NDT.S6430
Di Martino, R. M. C., Maxwell, B. D., & Pirali, T. (2023). Deuterium in drug discovery: progress, opportunities and challenges. Nature reviews. Drug discovery, 22(7), 562–584. https://doi.org/10.1038/s41573-023-00703-8
Owen, N. E., Barker, R. A., & Voysey, Z. J. (2023). Sleep Dysfunction in Huntington's Disease: Impacts of Current Medications and Prospects for Treatment. Journal of Huntington's disease, 12(2), 149–161. https://doi.org/10.3233/JHD-230567
Brugue, E., & Vieta, E. (2007). Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 31(1), 275-282. https://doi.org/10.1016/j.pnpbp.2006.06.014
Lachance, V., Bélanger, S. M., Hay, C., Le Corvec, V., Banouvong, V., Lapalme, M., ... & Kourrich, S. (2023). Overview of sigma-1R subcellular specific biological functions and role in neuroprotection. International journal of molecular sciences, 24(3), 1971. https://doi.org/10.3390/ijms24031971
Frequently Asked Questions
What are neurotransmitters and how do they relate to Huntington's Disease?
Neurotransmitters are like messengers in your brain that help brain cells talk to each other. In Huntington's Disease, the balance of these messengers, especially dopamine, gets messed up. This can lead to problems with movement, thinking, and mood. Medications often try to fix this imbalance.
How do VMAT2 inhibitors help with Huntington's Disease?
VMAT2 inhibitors are a type of medicine that helps control involuntary movements, or chorea, common in Huntington's. They work by lowering the amount of dopamine, a key messenger, available in the brain. By reducing dopamine activity, they can make these movements less severe. Deutetrabenazine is an example of a newer VMAT2 inhibitor.
Can antipsychotic medications be used for Huntington's Disease?
Yes, some antipsychotic drugs can help manage symptoms of Huntington's Disease. They can block dopamine receptors in the brain, which helps control excessive movements. Additionally, they can sometimes help with mood swings, irritability, and psychosis that can occur with HD. Newer types, called atypical antipsychotics, are often preferred because they may have fewer side effects.
How do medications like SSRIs help with mood in Huntington's Disease?
People with Huntington's Disease can experience depression and anxiety. Medications like SSRIs (Selective Serotonin Reuptake Inhibitors) work by increasing the levels of serotonin, another brain messenger, which plays a big role in mood. By boosting serotonin, these drugs can help lift feelings of sadness and worry.
What is the goal of developing new treatments for Huntington's Disease?
Scientists are working on many new ways to treat Huntington's Disease. Some aim to protect brain cells, others try to slow down the changes in the brain that cause the disease, and some focus on reducing the harmful huntingtin protein. The ultimate goal is to slow or stop the disease's progress and improve the lives of those affected.
What is gene therapy for Huntington's Disease?
Gene therapy is a cutting-edge approach that uses a harmless virus to deliver new genetic instructions into brain cells. These instructions can help reduce the amount of the harmful huntingtin protein or protect the cells. It's a complex treatment still in the early stages of development for HD.
How do drugs targeting the huntingtin protein work?
Some new drugs are designed to directly lower the levels of the huntingtin protein, which is the root cause of Huntington's Disease. They might do this by blocking the gene's instructions or by helping the body get rid of the harmful protein. The idea is to stop the disease from the source.
What are some of the challenges in developing medications for Huntington's Disease?
Developing medications for Huntington's Disease is challenging because the disease affects multiple parts of the brain and body. Also, getting treatments to the right places in the brain can be difficult. Many promising treatments are still in early research and need more testing to show they are safe and effective.
What is the difference between typical and atypical antipsychotics for HD?
Typical antipsychotics are older medications, while atypical antipsychotics are newer. Atypical antipsychotics are often preferred for managing symptoms like irritability and psychosis in Huntington's Disease because they tend to have a better side effect profile, meaning they might cause fewer unwanted reactions compared to the older typical ones.
Emotiv is a neurotechnology leader helping advance neuroscience research through accessible EEG and brain data tools.
Emotiv
